Bettina Cockroft
Directeur/Membre du Conseil chez ANNEXON, INC.
Fortune : - $ au 30/04/2024
Postes actifs de Bettina Cockroft
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ANNEXON, INC. | Directeur/Membre du Conseil | 20/01/2022 | - |
| Independent Dir/Board Member | 20/01/2022 | - | |
| CNS PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 08/05/2023 | - |
| Independent Dir/Board Member | 08/05/2023 | - | |
| Annexon Biosciences, Inc. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Bettina Cockroft
Anciens postes connus de Bettina Cockroft
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 30/09/2019 | 16/05/2023 |
| CYTOKINETICS, INCORPORATED | Corporate Officer/Principal | 01/08/2017 | 01/09/2019 |
Auris Medical AG
 Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland. | Directeur Technique/Scientifique/R&D | 01/09/2013 | 01/09/2016 |
Formation de Bettina Cockroft
| MIT Sloan School of Management | Masters Business Admin |
| University of Genoa | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 7 |
| Italie | 2 |
| Suisse | 2 |
Opérationnelle
| Director/Board Member | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
| Independent Dir/Board Member | 2 |
Sectorielle
| Health Technology | 6 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| CYTOKINETICS, INCORPORATED | Health Technology |
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| ANNEXON, INC. | Health Technology |
| CNS PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Auris Medical AG
Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland. | Health Technology |
| Annexon Biosciences, Inc. |
- Bourse
- Insiders
- Bettina Cockroft
- Expérience
